Windtree Therapeutics Inc
NASDAQ:WINT
Intrinsic Value
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of WINT.
Windtree Therapeutics Inc's market capitalization is 46.5m USD.
WINT stock price is 5.0701 USD.
WINT.
WINT. Open DCF Valuation
WINT. Open Relative Valuation
WINT has downside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
WINT has negative Free Cash Flow for the last twelve months.
WINT has positive Net Debt. This means that the company has more debt (16m USD) than cash and short-term investments (7m USD).
WINT's long-term assets (36m USD) exceed its long-term liabilties (29m USD).
WINT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -34% to -48%, and is approaching profitability.
WINT has negative Operating Income for the last twelve months.
WINT has negative Net Income for the last twelve months.
WINT's ROE (Return on Equity) has significantly decreased in the last 3 years from -43% to -199%, and is approaching profitability.
WINT's D/E (Debt to Equity) is very high and is equal to 2.07.
WINT's ROE (Return on Equity) for the past 12 months is negative and is equal to -199%.
WINT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -48%.
WINT's short-term assets (9m USD) exceed its short-term liabilties (4m USD).
WINT has negative three-year average ROE (Return on Equity): -114%. The company is not efficient at transforming stockholders' equity into net income.
WINT has negative three-year average ROIC (Return on Invested Capital): -47%. The company is not efficient at using invested capital to generate operating income.
WINT's Altman Z-Score is very low and is equal to -33.91.
Fundamental Analysis
Windtree Therapeutics Inc
Balance Sheet Decomposition
Windtree Therapeutics Inc
| Current Assets | 8.9m |
| Cash & Short-Term Investments | 7.4m |
| Other Current Assets | 1.5m |
| Non-Current Assets | 27.2m |
| PP&E | 1.7m |
| Intangibles | 25.3m |
| Other Non-Current Assets | 200k |
| Current Liabilities | 3.7m |
| Accounts Payable | 900k |
| Accrued Liabilities | 2.3m |
| Short-Term Debt | 500k |
| Non-Current Liabilities | 24.9m |
| Long-Term Debt | 15m |
| Other Non-Current Liabilities | 9.9m |
Earnings Waterfall
Windtree Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-16.1m
USD
|
|
Operating Income
|
-16.1m
USD
|
|
Other Expenses
|
-8.8m
USD
|
|
Net Income
|
-24.8m
USD
|
Free Cash Flow Analysis
Windtree Therapeutics Inc
WINT Profitability Score
Profitability Due Diligence
Windtree Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Windtree Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
WINT Solvency Score
Solvency Due Diligence
Windtree Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Windtree Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WINT Price Targets Summary
Windtree Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
WINT
is 3.06 USD
with a low forecast of 1.01 USD and a high forecast of 5.25 USD.
Ownership
WINT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
WINT Price
Windtree Therapeutics Inc
| Average Annual Return | -54.78% |
| Standard Deviation of Annual Returns | 37.45% |
| Max Drawdown | -100% |
| Market Capitalization | 46.5m USD |
| Shares Outstanding | 9 180 000 |
| Percentage of Shares Shorted | 0.43% |
Company Profile
Windtree Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
You don't have any saved screeners yet
